startups digital health weight loss glp-1 India's Opportunity: Why Are Betting Big on Quantum Health Partners with Vida

Lorem Ipsum has been the industry's standard dummy text ever since the 1500s.

Schedule: Subcutaneous injections 13 daily on an empty stomach for about 12 weeks

Saxenda 3 mg daily for weight management): Proven efficacy with 5-8% weight reduction and cardiovascular outcome benefits in the LEADER trial Dulaglutide (Trulicity 0.75-4.5 mg weekly): Convenient once-weekly dosing with demonstrated cardiovascular benefit in the REWIND trial Tirzepatide (Mounjaro for diabetes

This paper is thus conclusive in demonstrating that tirzepatide is associated with a risk of worsening of pre-existing DR but protective against developing any new DR or DME